BWA
XERS icon

Basecamp Wealth Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Basecamp Wealth Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.31K Buy
292
+33
+13% +$211 ﹤0.01% 1335
2026
Q1 		$1.5K Buy
+259
New +$1.72K ﹤0.01% 1467

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Basecamp Wealth Advisors's XERS Position: Q2 2026 in Review

Basecamp Wealth Advisors increased its Xeris Biopharma Holdings (XERS) stake by 13% in Q2 2026, buying an estimated $211 and bringing the position to 292 shares worth $2.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1335.

Basecamp Wealth Advisors first reported a position in XERS in Q1 2026 and has held it in 2 quarters since. 239 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Basecamp Wealth Advisors held 292 shares of Xeris Biopharma Holdings worth $2.31K as of Q2 2026.
  • Basecamp Wealth Advisors bought 33 Xeris Biopharma Holdings shares in Q2 2026, an estimated $211.
  • Xeris Biopharma Holdings made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1335 holding.
  • Basecamp Wealth Advisors first reported a position in Xeris Biopharma Holdings in Q1 2026 and has held it in 2 quarters since.
  • 239 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.